Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

• Main Authors: Zhi-Yong Liu (Author), Dan-Ying Zhang (Author), Xia-Hui Lin (Author), Jia-Lei Sun (Author), Weinire Abuduwaili (Author), Guang-Cong Zhang (Author), Ru-Chen Xu (Author), Fu Wang (Author), Xiang-Nan Yu (Author), Xuan Shi (Author), Bin Deng (Author), Ling Dong (Author), Shu-Qiang Weng (Author), Ji-Min Zhu (Author), Xi-Zhong Shen (Author), Tao-Tao Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib-resistant HCC are not systemically identified. This st...